Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Science & Co vs Zealthy

By GLP-1 ScorecardUpdated

Science & CoFactor scores not reassessed.
Site position #82

Higher score

ZealthyFactor scores not reassessed.
Site position #513

Lower score

Score comparison

Science & Co has the higher recorded score — 72.9/100 to 46.7/100.

Science & Co grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. States in its own footer that it is not a compounding facility, and explains its own asterisk in its own FAQ — two things almost nothing else here does.

Before you choose

Before comparing the headline prices, the Science & Co review and the Zealthy review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, Auren Rx vs Science & Co and Trellis Vitality vs Zealthy compare each of them with another graded program, and the list of alternatives to Science & Co ranks the programs closest to Science & Co on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the MEDGm review covers one graded close to these two, at 59.1/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueScience & Co +48
74
26
Dose & formulationScience & Co +10
74
64
Clinical oversightScience & Co +35
76
41
Labs & monitoringScience & Co +2
55
53
FulfillmentScience & Co +14
80
66
Contract termsScience & Co +41
82
41
Science & Co · top barZealthy · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricScience & CoZealthy
WeighScore72.9/10046.7/100
GradeCC
Site position#82#513
Semaglutide$149/mo month-to-month ($79 only on a 12-month plan)$151/mo on a 3-month supply, plus a separate membership (bundle $217 first month, then $297/mo; compounded)
Tirzepatide$199/mo month-to-month ($125 only on a 12-month plan)From $216/mo, plus a separate membership (bundle $349 first month, then $449/mo; compounded)
CoverageNot publicly listed34 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Science & Co

Site position #82 · C

Factor scores not reassessed.

Strengths

  • States twice in its footer that "Science and Co, Inc. is not a 503A or 503B compounding facility"
  • Its own FAQ names the commitment behind the headline: "Plans start at $125 a month on the 12 month plan"
  • The printed saving corroborates the reference price — 125 divided by 199 is 63%, exactly the "Save 37%" shown
  • "Same Price, Any Dose", with no hidden fees, no monthly membership and free shipping stated in the FAQ
  • Names its operating entity and state of incorporation, and says every batch is third-party tested

What to consider

  • The number it leads with is a twelve-month commitment; the per-month rates are $149 and $199
  • Only two figures are published per drug, so a three- or six-month plan cannot be priced without starting an intake
  • It says it is not a compounding facility but never names the pharmacy that is
  • No lab or monitoring protocol is published
  • Injection only on the pages read — no oral route and no brand lane
Zealthy

Site position #513 · C

Factor scores not reassessed.

FDAWarning letter issued to FitRX, LLC dba Zealthy in September 2025. See the FDA warning-letter database.

Strengths

  • Serves 34 states — meaningful nationwide footprint
  • Asynchronous model removes friction for patients who don't want a video visit
  • Independent licensed prescribers retain full clinical authority

What to consider

  • Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
  • Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
  • Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
  • Recently rebranded to Gronk Inc. amid active enforcement
  • FDA issued FitRX, LLC dba Zealthy a warning letter in September 2025; the letter is public in FDA's warning-letter database

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard